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Abstract 
 Background:		
Olfactory dysfunction affects a significant proportion of the population but appears to be 
more common in the elderly population (>20% of adults over 60 years old). Unfortunately, 
many sufferers face an apparent lack of therapeutic options when consulting with medical 
professionals. Method:		
We searched various electronic medical databases for the treatment of non-conductive 
olfactory dysfunction. After careful review of the abstracts and the full articles, we included 
publications that fulfilled our inclusion criteria and analysed the results. Results:		
A total of 38 publications were included in our review including 6 randomised control trials, 
14 cohort studies and 18 observational studies. Conclusion:		
Olfactory training appears to improve non-conductive olfactory dysfunction irrespective of 
the aetiology. Steroids appear to have some benefit, but this may be aetiology dependent and 
vitamin A and sodium citrate have shown some promise. Various other therapies have been 
investigated but high quality randomised control trials are still required to determine their 
place in managing this patient population. 
 
 
 
 
 
 
 
 
 
  
Introduction	
Olfactory disorders present a common problem in the population with estimates of a prevalence of 1-
5% and over 20% in the over 60’s [1-5]. Although they have not typically been associated with any 
morbidity, recent studies have shown a clear association with dementia [6] and have now also shown 
anosmia to be an independent risk factor of early mortality [7] even when cognitive impairment is 
controlled for. It is certainly clear that these patients face a poorer quality of life [8] and that their plight 
has traditionally been neglected by the medical fraternity [9], however specialist smell and taste clinics 
are now emerging to help to address the unmet need [10]. Those patients with a conductive disorder 
such as chronic rhinosinusitis have a more established treatment pathway [11], albeit that there is 
certainly a need for more randomised controlled trials in terms of both the medical and surgical 
management of the latter [12-18]. Conversely the management of non-conductive olfactory disorders has 
remained a more controversial area with many patients left untreated due to a perceived lack of 
therapeutic options. Very recently, the management of olfactory disorders has been brought into focus 
through the publication of international guidelines, which finally gives clinicians a framework for 
diagnostic work up and treatment [19]. 
The anatomical classification of the aetiology of olfactory dysfunction provides an opportunity for 
patients to be risk stratified for appropriate management. Conductive olfactory dysfunction results 
from distortion to nasal anatomy which leads to mechanical obstruction of the olfactory cleft and 
prevents the odorant from reaching the olfactory cleft [20]. Non-conductive dysfunction is usually due 
to damage to olfactory neuroepithelium, olfactory nerve or a central dysfunction due to damage to the 
olfactory processing pathway of the central nervous system [21].  In practice, it is often more complex 
as in some cases conductive and non-conductive dysfunction can co-exist, for example in chronic 
rhinosinusitis. For the purposes of this review, we have focused only on treatment options for patients 
with non-conductive dysfunction. Although non-conductive olfactory dysfunction is a good 
anatomical classification, it may be more useful to consider the therapeutic options by aetiology [22]. 
The most common aetiologies for non-conductive olfactory loss are further discussed below. 
Post-viral olfactory loss (PVOL) is the most common cause of olfactory dysfunction and usually 
follows an episode of upper respiratory tract infection. Viral pathogens such as rhinovirus, 
coronavirus and parainfluenza, have been detected in patients with PVOL [23].  Loss of cilia on 
receptor cells as well as remodelling and replacement of olfactory neuroepithelium with respiratory 
epithelium may be responsible for the reduced olfactory bulb volume and patchy distribution of 
neuroepithelia that has been demonstrated in PVOL patients [24,25].  
The prognosis of post-traumatic olfactory loss (PTOL) is often poor and usually dependent on the 
mechanism of injury [26]. In some cases, the presence of a haematoma and nasal fractures may lead to 
  
conductive obstruction of odorants to the olfactory cleft [27], whereas neuronal injury can result from 
transection or shearing of the olfactory nerve as it traverses the cribriform plate or gliosis of the cortex 
from contusion and/or intraparenchymal haemorrhage; all of the latter contributing to non-conductive 
olfactory loss [28]. PTOL occurs either immediately post injury or may be delayed reflecting an 
insidious pathology, possibly due to subsequent oedema [29]; in practice, patients with moderate to 
severe head injury often have delayed diagnosis of their olfactory sensory deficit as other life-
threatening injuries take precedence. A third of patients with post-traumatic anosmia will 
spontaneously improve, perhaps due to secondary resorption of any haematoma [30]. Where symptoms 
persist for more than twelve months, treatment is often difficult and more likely to be unsuccessful [27].  
Olfactory loss is well recognised in neurodegenerative conditions such as epilepsy, myasthenia gravis, 
Parkinson’s disease (PD) and Alzheimer’s disease [31,32]. The aetiology of olfactory dysfunction in 
these conditions remain unclear [33] and many of the treatments for these disorders are ineffective in 
improving olfactory function [34]. It has been reported that the olfactory loss in patients with PD occur 
more frequently than resting tremor and functional imaging has shown reduced activity in the 
hippocampus and amygdala of PD patients during odorous stimuli [35,36]. Histological studies have also 
shown pathological predisposition for central olfactory systems in patients with PD [37].  
Congenital anosmia is a relatively rare condition characterised by a complete lack of olfactory 
perception with aplasia or hypoplasia of the olfactory bulb. Two main classifications have been 
described; type I which is associated with somatic, gonadal, and developmental abnormalities (e.g., 
Kallman syndrome) and tends to be familial and type II which presents as isolated olfactory 
dysfunction in a phenotypically normal patient [38,39]. Where olfactory bulb aplasia exists, treatment 
will not be relevant, although attempts at grafting olfactory bulbs in rats have proven successful and 
perhaps may provide an option in the future [40]. 
This systematic review aims to establish the rationale for medical and non-medical treatments for this 
group of patients and explores the evidence behind current treatment options for non-conductive 
olfactory dysfunction.  Methods  
Based on the updated guidelines for systematic reviews of the Cochrane Collaboration Review Group, 
we performed a comprehensive electronic database search on medical and scientific databases 
(Pubmed, Google scholar, Cochrane database and Medline) using a specific search strategy. The 
Cochrane methodological filter for randomised control trials (RCTs) was utilised in addition to 
combing MeSH keywords and other relevant terms including, anosmia, hyposmia, pharmacotherapy, 
olfactory dysfunction, non-conductive, sensorineural, Post-infection, Post-trauma and congenital were 
searched to identify primary comparative studies on treatment and management options for non-
  
conductive anosmia. Our searches were supplemented by screening through the references of our 
initial search results. Comparative studies of any design examining the management outcome of 
patients with non-conductive anosmia were included. The level of evidence was stated for each 
publication and by following the modified GRADE quality assessment; the quality of evidence for the 
treatment option was graded  Inclusion	Criteria	
All published studies on treatment of non-conductive olfactory loss including: 
• Randomised Control Trials  
• Cohort studies  
• Preliminary results on ongoing research  Exclusion	Criteria	
• Case reports 
• Non-English publications Results 
The search resulted in 240 citations from which the relevant studies were selected for review and 
potential relevance. From this, 172 articles were excluded using the inclusion and exclusion criteria 
stated below, 68 abstracts were reviewed and the full articles of 38 citations fulfilled the criteria of 
inclusion. These articles were human studies primarily related to outcomes of management in patients 
with non-conductive olfactory dysfunction; 6 randomised controlled trials and 32 other outcome 
studies were included (Tables 1-5). 
 
 
 
 
 
 
 
 
  
Table 1: Post Viral Olfactory Loss 
Olfactory Training 
Study  Study Design 
Patients 
/Aetiology 
Olfactory 
function Test Intervention  
Follow 
up 
(weeks) Results 
Level of 
evidence 
Polleti et al 
2017 [41] 
Prospective single 
blinded  
PVOL, n=70 
PTOL, n = 26 
Sniffin sticks Olfactory training with heavy molecular weight (HMW) odorant 
(>150g/mol, n=48 ) versus low molecular weight(LMW) odorant 
(<150g/mol, n=48) for 5months 
20 Overall significant 
improvement in olfaction 
(PVOL>PTOL) 
No difference between 
HMW and LMW 
2B 
Sorokowska et 
al 2017 [42] 
Meta-analysis Mixed aetiology, 
13 articles 
variour Olfactory training in a olfactory loss of different aetiologies  Significantly positive 
response to training  
1 
Konstantinidis 
et al 2016[43] 
Prospective 
controlled  
PVOL n=111,  Sniffin Sticks Olfactory training (12 week training Vs 56 week training Vs Control ) 56 Long term training yields 
better function 
2B 
Altundag et al, 
2015 [44] 
Prospective, 
controlled 
PVOL, n=85 Sniffin Sticks Olfactory training  36 Longer Olfactory  training 
with change of odour was 
effective in terms of odour 
discrimination and 
identification 
2B 
Damm et al, 
2014 [45] 
prospective 
randomised single 
blinded controlled  
PVOL, n=144 Sniffin’ Sticks High concentrations of 4 odours Vs Low concentrations 38 Olfactory training was 
significantly more effective 
with high concentration of 
odours and dysfunction <12 
months 
2B 
Geißler  et al, 
2014[46] 
Prospective study  PVOL, n=39 Sniffin’ Sticks suprathreshold concentations of 4 odours  32 Longer duration of training 
(≥32 weeks) increased 
effectiveness of training 
2C 
Medical Management 
Study  Study Design Patients 
/Aetiology 
Olfactory 
function Test 
Intervention  Follow 
up 
(weeks) 
Results Level of 
evidence 
Philpott et al  
2017 [47] 
Randomised 
control trial 
Non-conductive 
olfactory loss 
(n=55) 
Phenyl ethyl 
Alcohol (PEA)  
0.5ml of 9 % sodium citrate versus placebo (sterile water) 120 
minutes 
32% improved odour 
sensitivity  in treated arm 
1B 
Whitcroft et al 
2017[48] 
Randomised 
control trial 
PVOL, n=49 Sniffin’ Sticks 1 mL sodium citrate solution versus placebo (1 mL physiological 
sodium chloride solution) 
30 
minutes 
statistically significant (but 
not clinically significant 
improvement in composite 
threshold + identification 
scores following treatment 
with sodium citrate, 
1B 
  
compared with placebo. 
Hummel et al 
2017 [48] 
Retrospective 
cohort study 
PVOL & PTOL 
(n=170) 
Sniffin Sticks Topical Vitamin A  10,000 IU/day for 8 weeks  + olfactory training for   
versus olfactory training for 12 weeks  
45 Significant improvement in 
Vitamin A group (37%) 
2B 
Henkin et al 
2017 [49] 
Prospective 
controlled 
Multiple 
aetiologies 
PVOL= 11 
Congenital =9 
Olfactometry 
(odour detection 
and recognition 
for four odours) 
Theophylline 200-800mg once a day for 2 to 10 months 40 Increased nasal mucus sonic 
hedgehog levels associated 
with improved detection and 
perception of smell 
2B 
Whitcroft et al, 
2016 [50] 
Prospective 
Randomised 
cohort Study  
Hyposmia (n=57, 
7 PVOL) 
Sniffin Sticks Topical sodium citrate versus placebo (sodium chloride) 30 
minutes 
Statistically significant 
improvement in PVOD 
2B 
Dai et al, 2016 
[51] 
Prospective cohort 
study  
PVOL (n=50-
Failed steroid 
and Vitamin B 
treatment) 
 University of 
Pennsylvania 
smell 
identification test 
Traditional Chinese acupuncture with acupoints at the nasolabial grove 
and middle turbinates 
12 Improved UPSIT score in 
TCA group from 18.24 to 
22.08 compared to the 
observation group (17.36 to 
18.64) 
2B- High 
risk of 
bias 
Kim et al, 2016 
[30] 
Retrospective 
study 
Olfactory 
dysfunction    
(n=491,  178 
PVOL) 
Connecticut 
Chemosensory 
Clinical Research 
Center test 
(threshold test) and 
Cross-cultural 
Smell 
Identification Test 
oral prednisolone 40mg reducing in third week by 5mg/day Vs 
mometasone furoate topical 2sprays Vs combination of oral and topical 
steroid 
4 59.6% recovery in all group. 
Combination and single oral 
steroid statistically better 
than topical steroid alone 
4 
Blomqvist et al, 
2013 [52] 
Randomised 
Control Trial 
(RCT) 
PVOL ( n=40) Butanol threshold 
test<8 
40mg of prednisolone -reducing dose then topical fluticasone propionate 
for all patients, then randomised to placebo, control and continuation of 
flixonse 
24 Initia40mg of prednisolone l 
improvement 
2B 
Henkin et al 
2012 [53] 
Open labelled 
prospective study 
Multiple 
aetiologies n=10 
Olfactometry 
(odour detection 
and recognition for 
four odours) 
Patients who had sub-optimal response to oral theophylline (200-
800mg) where treated with intranasal theophylline 20ug/day/nostril 
4  Statistically significant 
improvement in olfactory 
function in this subgroup 
2C 
Reden et al, 
2012 [54] 
RCT PVOL & PTOL 
(n=54) 
Sniffin Sticks Vitamin A (10,000iu capsule, once a day for 3 months Vs placebo) 20 No statistical significance in 
either PVOD or PTOL 
groups 
1B 
Schriever et al 
2012 [55] 
Retrospective 
cohort study 
All aetiologies 
(n=425, 27 
PVOL) 
Sniffin Sticks oral methylprednisolone 40mg reducing dose for 2weeks  2 Statistically significant 
improvement in sniffing 
sticks score by 6 points or 
more 
2C 
  
 
Reden et al, 
2011[56] 
RCT PVOL, n=55 Sniffin Sticks 100mg BD monocycline Vs placebo 28 No statistical difference 
although 15% improved in 
treated group against 20% 
spontaneously improved 
1B 
Vent et al, 2010 
[57]  
Prospective study   PVOL, n=30 Sniffin Sticks TCA ( The following injection points were chosen: DuMai 16 and 20, 
Di20, Lu 7 and 9, Ma 36, and Ni3) repeated weekly for 10 weeks Vs 
Oral vitamin B complex for 12 weeks 
12 Statistical improvement in 
TCA group (8/15) compared 
to Vitamin B group (2/15) 
2C 
Seo et al, 2009 
[58]  
RCT PVOL, n=71 Butanol threshold 
test.(anosmia score 
between 0-3), 
cross culture smell 
identification test 
(CCSIT) 
monotherapy(prednisolone-30 mg/d for the first 3 days, 20 mg/d for 4 
days and 10mg/d for  7 days) combination (prednisolone/ginkgo biloba-
80mg tds for 4 weeks) +All given mometasone furoate for 4/weeks 
4 Statistically significant 
improvement BTT (4.8-6.9) 
and CCSIT 
1B- No 
control 
group 
Gudziol et al 
2009 [59] 
Prospective 
longitudinal pilot 
study  
n=19, 4 
functional 
hyposmia  
Sniffin sticks 200mg IV or oral pentoxifylline 2days Increased olfactory 
sensitivity in younger 
pateints 
2C 
Fukazawa et al, 
2005 [60] 
Prospective study  PVOL, n=133 T&T olfactometer 
and VAS 
5mg intranasal injection of dexametasone or betametasone every 2 wks 
for 8wks 
12 49.6% improvement using 
T&T olfactometer & visual 
analogue scales 
2C 
Heilmann et al, 
2004 [61] 
Prospective study  PVOL, 
Idiopathic, 
sinonasal 
disease, n=92 
Sniffin Sticks 40mg oral prednisolone reducing dose for  3 wks Vs topical 
Mometasone Propionate for 3 months 
 12 oral steroids improved sig 
no sig in top 
2C 
Quint et al, 
2002 [62] 
RCT non-conductive, 
n=77 
Sniffin Sticks and 
BTT 
120mg/day for 4 weeks caroverine vs zinc sulphate (control) 4 Anosmic patients improved 
but significant improvement 
in hyposmic patient  
1B- No 
control 
group 
Hummel et al. 
2002 [63] 
Prospective 
clinical trial  
PVOL, n=23 Sniffin Sticks alpha lipoic acid 600mg/day for 3 to 11 months 16 Statistically significant 
improvement in olfactory 
function especially younger 
patients 
2B 
Aiba et al, 1998 
[64] 
Retrospective 
cohort study 
non-conductive , 
n=426 & PVOL, 
n=48 
Visual Analogue 
Scale 
300mg zinc  sulphate/day for 1  month VS zinc + steroid (topical) + 
vitamin b Vs top steroid +Vitamin B 
2 No sig4nificant 
improvement in PVOD 
group 
2C 
  
  
  
Table 2: Post traumatic Olfactory Loss 
Study  Study Design Patients /Aetiology Olfactory function Test Intervention  Follow up  Results Level of 
evidence 
Konstantinidis, et 
al, 2013 
Prospective 
study 
119, PTOL and 
PVOL 
sniffin sticks olfactory training group Vs control  16 significant improvement training 
groups 
2C 
Kim et al, 2016 
[30] 
Observational 
study 
491 olfactory 
dysfunction, 96 
PTOL 
Connecticut Chemosensory 
Clinical Research Center test 
(threshold test) and Cross-
cultural Smell Identification Test 
oral prednisolone 40mg reducing in 
third week by 5mg/day Vs 
mometasone furoate topical 2sprays 
Vs combination of oral and topical 
steroid 
4  12.5 % improvement mainly in those 
treated early  
4 
Jiang et al, 2015  Prospective 
randomised 
control study 
145 PTOL Odour discrimination test with 
phenyl ethyl alcohol 
Group 1 = 39 (steroid-1mg/kg/day) -2 
weeks tapering and zinc- 10mg TDS 
PO- 1 month, group 2=35 zinc , group 
3 = 34 steroid, group 4 = 37 – no 
treatment 
36  The recovery of olfactory function 
was observed in 11 patients (28.2%) 
in group 1, in 9 (25.7%) in group 2, 
in 4 (11.8%) in group 3, and in 1 
(2.7%) in group 4. The recovery 
rates of olfactory function of groups 
1 and 2 were significantly higher 
than the recovery rate of group 4  
1B 
Fujii et al, 2001 Prospective 
study 
18 PTOL T&T olfactometer(OT & IT) and 
Intravenous Alinamin 
injection of dexamethasone (4mg/ 
0.5mls) & Oral Vitamin B12 and 
Adenosine triphosphate  
5 months 35% improvement in olfactory 
function  
2C 
Aiba et al, 1998 
[64] 
Retrospective 
cohort study 
426 patient,95 PTOL VAS 300mg zinc  sulphate/day for 1  
month VS zinc + steroid(topical) +vit 
b Vs top steroid +Vit B 
2 weeks significant improvement in PTOL 
group 
2C 
  
Ikeda et al, 1995 
[65] 
Observational 
study 
17 PTOL T&T olfactometer(OT & IT) and 
Intravenous 10mg thiamine 
propyl disulphide  
12 intranasal betametasone/ 5 oral 
prednisolone 30-60mg OD 10-14 days  
6-12 months 3 of 5 improved and 1 out of 12 4 
 
 
Table 3: Olfactory loss in patients with Neurodegenerative conditions 
Study  Study Design Patients /Aetiology Olfactory function Test Intervention  Follow up  Results 
Level of 
evidence 
Haehner et 
al, 2013 
[66] 
Prospective study 70 Parkinson’s Disease sniffin sticks olfactory 
training 
12 weeks significant improvement in those who had olfactory training  2C 
Hummel et 
al 2005 [67] Prospective study 11  Parkinson’s patients  sniffin sticks 
Deep brain 
stimulation  Not stated Odour identification significantly increase with stimulation 4 
 
Table 4: Idiopathic Olfactory Loss 
Study  Study Design Patients /Aetiology Olfactory function Test Intervention  
Follow 
up  Results 
Level of 
evidence 
Mavrogeni et 
al, 2016 [68] 
Observational 
study 
5, non-conductive 
loss- idiopathic 
Subjective  Monthly 1ml of platelet rich plasma via 
30G needle, 1 cm from olfactory area 
over 3 months 
Not 
stated 
4 complete return of olfactory function. 
THIS WAS A CASE SERIES WITH NO 
OBJECTIVE MEASURE OF 
OLFACTORY FUNCTION 
4 
Duncan et al, 
1962 [69] 
Prospective non-
randomised 
56 patients with 
multiple aetiologies 
(21-PVOL, 17 
idiopathic) 
odour threshold  Vitamin A, subcutaneous injection (52) 
or oral tabs(3) or emulsion(1) 
2years Marked or perceptible improvement in 46 
(injection) not randomised. Oral tablet 
group where given injection when it was felt 
that their treatment was failing 
2C 
Kim et al, 
2016[30] 
Observational 
study 
491 olfactory 
dysfunction, 89 
idiopathic 
Connecticut Chemosensory 
Clinical Research Center test 
(threshold test) and Cross-cultural 
Smell Identification Test 
oral prednisolone 40mg reducing in 
third week by 5mg/day Vs mometasone 
furoate topical 2sprays Vs combination 
of oral and topical steroid 
4 weeks No statistically significant improvement  4 
Heilmann et 
al 2004 [61] 
Prospective 
study  
 Differing aetiologies 
n = 192, (Idiopathic= 
85, PVOL=72) 
sniffin sticks Oral prednisolone Vs local 
corticosteroids Vs Systemic Vitamin B 
6months Improvement following systemic and local 
corticosteroids; also improvement with 
systemic Vitamin B after 6 months  
2C 
 
  
 
Table 5: Congenital Olfactory loss 
Study  Study Design Patients 
/Aetiology 
Olfactory function Test Intervention  Follow 
up  
Results Level of 
evidence 
Henkin et, 
2016 [70] 
Observational 
study 
19 congenital 
hyposmia- non 
genetic 
Detection thresholds (DT), recognition thresholds (RT), magnitude estimation (ME) 
and hedonics (H) for four odours [pyridine (pungent), nitrobenzene (bitter almond), 
thiophene (petroleum) and amyl acetate (banana)] using a standard three stimuli, 
forced choice staircase technique  
theophylline, 200–800 
mg daily for 2–36 
months 
36 
months 
63% significant 
initiation of smell 
function  
2C 
 
  
  
Table	6:	Treatment	options	based	on	aetiology	
 		
 
 
 
 
 
 
 
 
 
 
a) Post viral olfactory loss 
Intervention  Grade of Recommendation Effect 
Olfactory training B Positive 
Steroid B Positive 
Theophylline B (Not specific to PVOL patients) Positive 
Sodium Citrate  B Positive 
N-methyl D-aspartate antagonist (caroverine) C (hyposmic patients improved) Positive 
Traditional Chinese Acupuncture C Positive 
Alpha lipoic acid C Positive 
Vitamin A/B C Mixed  
Monocycline C No effect 
Zinc sulphate C No effect 
 
b) Post traumatic olfactory loss 
Intervention  Grade of Recommendation Effect 
Olfactory training B Positive 
Steroid B Positive 
Steroid + Zinc sulphate C Positive 
 
c) Congenital olfactory loss 
Intervention  Grade of Recommendation Effect 
Theophylline D Positive 
 
d) Neurodegenerative olfactory loss 
Intervention  Grade of Recommendation Effect 
Olfactory training C Positive 
Deep brain stimulation  D Positive 
  
 
 Table	7:	Overall	recommendation	for	various	treatment	options		
Intervention  Number of 
publications 
Double blinded  Summary of 
results 
Expected 
therapy effect 
Olfactory training 6 No good effect (+) 
Steroid 12 yes good effect (+) 
Theophylline 3 No Good effect (+) 
Sodium Citrate  4 yes anecdotal (+) 
Caroverine 1 No anecdotal (+) 
Antibiotics 
(minocycline) 
1 yes No effect  nil 
Vitamin A 3 No inconsistent (+) 
Vitamin B 4 No  No effect ? 
Vitamin C 0 / ?   
Vitamin E 0 / ?   
Strychnine 1 No anecdotal  ? 
Traditional 
Acupuncture 
2 yes anecdotal (+) 
Alpha lipoic acid 1 No anecdotal ? 
Zinc sulphate 3 no No effect nil 
Surgery 1 no Good effect in 
patients with 
phantosmia 
 (+) 
 
 
  
Discussion  
Post-Viral (Infectious) Olfactory loss/dysfunction (PVOL)  
Conservative management 
Reden et al, 2006 studied 262 patients with PVOL and showed a 32% recovery rate without any 
treatment after 14 months of follow up; 6% of the patients in this cohort had worsening olfactory 
function [27]. In a study of 542 patients using the University of Pennsylvania smell identification test 
(UPSIT), London et al 2007 demonstrated that over one third of patients had spontaneous 
improvement of olfaction. Prognosis was found to be unrelated to aetiology and the rate of recovery 
was dependent on the degree of initial loss, age and the duration of olfactory loss [71]. Therefore, with 
all patients, a discussion about the prognosis and likelihood of spontaneous recovery should be 
undertaken as well as the possibility that in some individual circumstances, a conservative approach 
may avoid problems posed with medical options where contraindications or interactions exist due to 
their medical and drug history. 	Olfactory	Training	
There is good evidence to suggest that olfactory training improves olfactory function in patients with 
PVOL. There is a single meta-analysis and several prospective controlled studies that have shown 
improved olfactory function in patients in whom long term (>32 weeks) and high concentrations of 
odorants have been used for olfactory training [41-46]. The classic olfactory training involves a five-
minute exposure to four different odorants twice a day [43]. These four odorants (phenyl ethyl alcohol, 
eucalyptol, citronellal and eugenol) are said to define the six most significant odour qualities of the 
olfactory realm and have been shown to improve olfactory loss after training for 12 weeks or more. 
The modified olfactory training was first introduced by Altundag et al 2015. The four-odorant used in 
the classic odorant training was initially used for 12 weeks, followed by menthol, thyme, tangerine 
and jasmine for another 12 weeks and lastly green tea, bergamot, rosemary, and gardenia were used. 
This study was able to show better odour discrimination and identification in patients treated with the 
modified technique [44]. 
As olfactory training is a non-invasive low risk treatment strategy that can be self-directed, the vast 
majority of affected individuals can be advised to pursue this, however they will need encouragement 
in undertaking the full course of training as the results may not always be instantaneous. Patient 
forums such as those provided through the charity Fifth Sense [72] are useful ways for patients to 
engage with fellow sufferers who have adopted the same strategies. 	
  
Oral	and	Intranasal	Corticosteroids		
Studies exploring the use of various formulations, routes and doses of steroid in the treatment of 
PVOL patients have shown favourable outcomes [30,52,55,58]. There are however no large randomised 
control trials focused on this subset of patients. Various comparative studies have shown 
improvement in olfactory function in 25-55% of patients following treatment with steroids. In a 
randomised control trial by Seo et al 2016, 40mg oral prednisolone as monotherapy or combination 
with 80mg of ginkgo biloba for 4 weeks was shown to have significant improvement in olfactory 
function. This study did not include a control placebo group to ascertain if the improvement was 
statistically significant in comparison to an untreated group [58]. The question of oral versus topical 
steroids was exploited by Kim et al 2016, in a retrospective study and showed that combination of 
oral and topical steroids or oral steroid as monotherapy significantly improves olfactory function 
compared to montherapy with topical steroids [30]. Heilman et al, 2004 showed significant 
improvement in PVOL patients treated with oral prednisolone whilst adding topical mometasone 
propionate conferred no significant improvement in this group of patients. It has however been 
suggested that the technique of delivery of topical steroids may be the reason for the poor response to 
topical steroids; the Kaiteki position (patients lie on the side with their head tilted and chin turned 
upward) allows nasal drops to reach the olfactory cleft in 96% of decongested noses and 75% in the 
non-decongested nose [73]. Intranasal injection of steroid has also been shown to improve significantly 
the olfactory function in this group of patients [60]. Non-Steroid	medical	management	
Theophylline: The mechanism of action of theophylline on olfactory neuroepithelium is not fully 
understood. Theophylline is postulated to inhibit phosphodiesterase and increase growth factors such 
as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) therefore 
aiding olfactory neuroepithelium regeneration [74]. There are no specific studies on theophyllline in 
patients with PVOL. Henkin et al, 2009 evaluated 312 patients with hyposmia of multiple aetiologies 
treated with 200mg-800mg of theophylline and was able to show 50.3% of patients have statistically 
significant improvement in olfactory function. These patients were followed up between 6-72 months 
[49]. Henkin et al 2012 was also able to show improvement in olfactory function after treatment with 
intranasal theophylline in a pilot study [53].  Interpretation of these results should be viewed with 
caution as they have only been performed in one centre using non-standardised olfactory tests. 
Sodium Citrate: Intranasal sodium citrate by its ability to buffer calcium ions has been shown to 
reduce mucosal calcium ions with subsequent reduction in negative feedback and increasing 
sensitivity to odorants.  Whitcroft et al 2016 performed a prospective placebo controlled trial of 
monorhinal treatment of sodium citrate versus sodium chloride for patients with olfactory loss 
  
(multiple aetiologies, n=57) and showed improved olfactory threshold and identification only in the 
PVOL cohort (n=7) [50] . Philpott et al, 2017 compared a single application of 0.5ml of 9% sodium 
citrate per nostril versus sterile water (n=55) in a randomised controlled trial and showed statistically 
significant improvement in olfactory function using olfactory thresholds for phenyl ethyl alcohol 
(PEA), 1-butanol and eucalyptol with thresholds measured up to 2 hours after intervention showing an 
effect lasting between 30 and 120 minutes after application [47]. In the latter study, the response rate 
was 1 in 3 of the treatment group as compared to none in the control group. Most recently the Dresden 
group performed a follow on study where they found some improvement in the treatment arm, but this 
did not reach clinical significance[48]. 
N-Methyl D-Aspartate (NMDA) antagonist: The mechanism of the NMDA antagonist, Caroverine 
on the olfactory neuroepithelium, is not entirely clear.  Its mode of action is probably through its 
inhibition of the olfactory bulb feedback mechanism. Quinn et al, 2002 conducted a randomised 
control trial on 71 patients with non-conductive loss. The treatment group (n =51), had 120mg/day of 
caroverine and the control group (n=26), had 140mg/ day of zinc sulphate). Both groups were treated 
for 4 weeks and the treatment group had statistically significant improvement in olfactory function in 
both hyposmic and anosmic patients. 
Alpha lipoic acid (ALA): Is a fatty acid mainly used in the treatment of diabetic neuropathy, it 
stimulates the expression of nerve growth factors; substance P and neuropeptide Y, and has anti-
oxidative and neuroprotective capabilities. Uncontrolled prospective study of 23 patients with PVOL 
treated with 600mg/day of ALA for an average of 4.5 months by Hummel et al 2002 showed at least 
moderate improvement in olfaction in 61% of the participants.   
Vitamin A: Vitamin A is known for its regenerative ability and it has been suggested that it improves 
olfaction by aiding regeneration of olfactory neuroepithelium. Duncan and Briggs in 1962, reported 
improvement in olfactory function in 50 of 56 patients following treatment with vitamin A. Reden et 
al in 2012 however, found no improvement in olfactory function in PVOL and PTOL patients 
following oral administration of 10000IU/day of vitamin A for 3 months in a double blinded, placebo-
controlled trial using Sniffin’ Sticks olfactory test [54]. More recently Hummel et al 2017, reported 
statistically improved olfaction in PVOL and PTOL patients in a retrospective cohort study (treatment 
group n=124, olfactory training with 10000 IU of intranasal Vitamin A and control group, n=46 had 
olfactory training) using sniffin sticks test assessment [48]. This study however has inherent problem of 
any retrospective study in that, the inability to control the differences between the groups may have 
confounded the results.  
Minocycline and Zinc sulphate: Minocycline has been shown to act as an anti-apoptotic agent which 
may improve olfactory function. Randomised prospective placebo-control double blinded study by 
  
Reden et al, 2011 using oral 50mg/bd of minocycline versus placebo for 3 weeks and found no 
statistical difference between the two groups [56].   
Most of the studies using Zinc Sulphate have reported no statistically significant improvement in 
olfactory function post treatment especially in the PVOL group. Various doses have been used, 
ranging from 120mg daily to 300mg daily doses. Aiba et al, 1998 performed a randomised control 
trial with three groups (group A= treated with 300mg of oral zinc sulphate only, group B= Zinc 
sulphate 300mg + topical mometasone prioponate and group C= topical mometasone propionate + 
Vitamin B) and reported no improvement in PVOL group although the PTOL group statistically 
improved with zinc sulphate. Non-Medical	Management	
Traditional Chinese Acupuncture: A non-randomised prospective study by Vent et al, 2010 was 
able to show significant improvement in PVOL patients with traditional Chinese acupuncture (n=15) 
compared with those treated with vitamin B [38]. This paper however had significant selection bias 
which may have affected the results. Dai et al, 2016 showed statistically significant improvement in 
olfactory function in PVOL patient who had failed to improve on steroid and vitamin B treatments 
following treatment with traditional Chinese acupuncture with acupoints along the nasolabial grove 
and the middle turbinate [39]. Post	Traumatic	Olfactory	loss	
 Conservative	Management	
Spontaneous recovery of olfactory function is said to occur in a third of patients with post-traumatic 
olfactory loss (PTOL). The recovery may be due to secondary resorption of haematoma or resolution 
of initial nerve oedema [40]. Where symptoms persist for more than six months, treatment is often 
difficult and unsuccessful. Surgical management of obvious nasal deformities may improve the 
olfactory function, those who continue to be symptomatic, often have only a handful of options with 
little evidence. 	Olfactory	Training	
Olfactory training has been shown to have significant effect in patients with PTOL. Training with low 
molecular weight molecules (<150g/mol) has been shown to be beneficial in this group of patients.  
Compared with PVOL patients, PTOL patients tend to benefit less from olfactory training possibly 
due to irreparable damage to the olfactory nerve [41].  
  
Steroid	Management	
Studies have shown 10-30% improvement in olfactory function in patients treated with either oral or 
intranasal steroids [42,43]. Jiang et al, 2015 randomised 145 patients with PTOL into three treatment 
arms (Steroid, Zinc, combination of steroid and zinc) and a non-treatment arm and showed significant 
improvement in patients who had zinc sulphate as monotherapy and those treated with combination 
therapy (zinc sulphate and prednisolone) [44].  Non-Steroid	Medical	Management	
Zinc sulphate has been shown to offer significant improvement in olfaction by Aiba et al 1998 in 
PTOL patients. This was a small prospective cohort study, there has been little randomised studies to 
support this, other than the Taiwanese study mentioned above.  
Theophylline has been shown to improve olfactory function in PTOL patients. Oral theophylline and 
intranasal theophylline have been proposed for treatment, although as aforementioned, specific 
evidence for its use is confined to studies from only one centre without use of an internationally 
validated psychophysical olfactory test [45]. Olfactory	loss	in	neurodegenerative	disease	
Neurodegenrative changes in the olfactory cortex are more commonly observed in patients with 
Parkinsons disease (PD) compared to age matched healthy individuals [75]. Severe hyposmia is a 
prodromal symptom of Parkinson Disease [76] and is considered one of the biggest risk factors of 
mortality in PD. Studies have demonstrated that olfactory disturbance in patients who were 
asymptomatic with the disease subsequently became symptomatic [75,78]. There is evidence to suggest 
that olfactory training with 4 odorants twice daily for 12 weeks significantly improves olfactory 
function compared to non-training group in PD patients [66,67].  
Deep brain stimulation (DBS) has been added to the therapeutic armamentarium in the management 
of patients with PD.  Hummel et al, 2005 found deep brain stimulation of the subthalamic nucleus of 
PD patients improved odour discrimination while having no effect on odour thresholds indicating a 
possible positive effect in cognitive processing of olfactory function [67].  
Cholinesterase Inhibitor Velayudhan et al conducted an unblinded and uncontrolled study and 
demonstrated that the cholinesterase inhibitor, donepezil, could greatly improve olfactory function of 
Alzheimer’s disease (AD) patients [79]. Congenital	Anosmia		
There is little literature on patients with congenital anosmia. It is widely accepted that syndromic 
patients with anosmia have little chance of gaining the ability to smell, although the idea of gene 
  
therapy may prove to be useful in the future. Henkin et al 2016, however showed 63% improvement 
in olfactory function in 19 patients with isolated congenital anosmia (type II) following treatment with 
theophylline [70]; again this is the same caveat for the results from this one centre as above. In practice, 
the majority of patients with congenital anosmia have olfactory bulb aplasia regardless of whether 
they have Kallman syndrome or not [80].  Conclusion	
Non-conductive olfactory loss can be challenging to manage and as evidence for the management of 
these disorders is limited and there is a growing need for good randomised control trials. 
Notwithstanding this, there is clear evidence for the use of olfactory training in the treatment of non-
conductive olfactory loss irrespective of the aetiology19. The evidence for the use of other medical 
treatment according to aetiology is quite weak but it is clear from this review that there are additional 
management options available to them, albeit that a discussion with the patient about the potential 
limitations and pitfalls and also explaining that with certain medications they will not be licenced for 
the treatment of olfactory disorders. In terms of oral medications, steroids and theophylline have 
shown some promise in the treatment of PVOL and PTOL patients and with topical treatments, 
sodium citrate and vitamin A have also shown some good potential. The ENT research community 
now needs to convince funding bodies for the need to deliver more RCTs that can usefully inform 
clinicians on the place of these therapies and help to treat this much maligned group of patients. 
Initiatives such as the Generate project in the UK81, may help take steps in this direction. 
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